Semler Scientific Inc Stock Price, News & Analysis

Semler Scientific (SMLR) announced on April 19, 2023, that Eric Semler has been appointed as Chairman of the Board and William H.C. Chang as a new independent director. Both are significant shareholders, owning over 20% of the company. The board will temporarily expand to seven members and later revert to five. Semler and Chang bring extensive experience in capital allocation and corporate governance, which is expected to enhance strategic planning. Dr. Wayne T. Pan, CEO, expressed optimism about the new appointments. Eric Semler emphasized the company's potential in diagnosing diseases and maximizing shareholder value through three main strategies: optimizing core business, developing new products, and leveraging the company's substantial cash position, which is approximately 25% of its market cap.

Semler Scientific, Inc. (NASDAQ: SMLR) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 4:30 PM ET. CEO Wayne T. Pan, Ph.D., M.D., and Renae Cormier will present an overview of the company and engage in one-on-one calls with investors on April 18. A live webcast of the presentation will be accessible through the company's investor section on its website, with an archive available for 90 days. Semler Scientific focuses on developing technology solutions for healthcare efficiency, including the QuantaFlo test for cardiovascular disease diagnosis and the Insulin Insights™ software for diabetes treatment.

On April 3, 2023, Semler Scientific (SMLR) discussed the recent CMS 2024 Medicare Advantage and Part D Final Rate Announcement, specifically its decision to remove peripheral artery disease (PAD) without complications from the risk adjustment model. Despite this, CEO Wayne T. Pan expressed confidence in the importance of screening at-risk Medicare patients using the QuantaFlo® product. A three-year phase-in period allows continued screening, supporting the collection of clinical outcome data. Studies indicate that earlier diagnosis of PAD can lead to significant cost savings and improved patient outcomes. Semler aims to maintain rigorous testing protocols to benefit healthcare providers and patients.

Semler Scientific (Nasdaq: SMLR) reported a Q4 2022 revenue of $13.8 million, reflecting a 20% increase year-over-year, with net income rising 113% to $3.2 million. For full year 2022, revenues reached $56.7 million, a 7% increase, while net income decreased by 17% to $14.3 million. Cash position improved to $43.1 million. A transition in leadership was announced, as CEO Doug Murphy-Chutorian will step down, succeeded by Wayne T. Pan effective April 3, 2023. The company expects Q1 2023 revenue between $17.4 million and $17.8 million but has withheld guidance for the entire year.

Semler Scientific, Inc. (NASDAQ: SMLR) announced on March 21, 2023, that Doug Murphy-Chutorian, M.D. will step down as CEO but remain on the board through 2024. Wayne T. Pan, M.D., Ph.D., M.B.A., currently a board member since May 2014, will take over as CEO effective April 3, 2023. Dr. Pan brings over 20 years of wide-ranging healthcare experience, including his role as a medical director at Banner Health. In his statement, Dr. Pan expressed confidence in Semler's diagnostic tools, emphasizing their potential to improve cardiovascular care and enhance shareholder value.

S Santa Clara, Calif., March 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ: SMLR) announced it will report its financial results for Q4 and full-year 2022 on March 21, 2023, after U.S. markets close. CEO Doug Murphy-Chutorian will lead a conference call at 4:30 PM ET, alongside key executives from finance, marketing, and communications. Participants can pre-register for the call or dial in directly. Semler's mission focuses on improving clinical effectiveness through innovative healthcare solutions, including the FDA-cleared QuantaFlo® test for cardiovascular diseases.

Semler Scientific (SMLR) announced a study published in the Journal of Preventive Medicine validating QuantaFlo's role in diagnosing heart dysfunction. The study revealed a significant correlation (p<0.01) between QuantaFlo measurements and cardiac echocardiography, the gold standard in heart failure diagnosis. QuantaFlo offers a quick, non-invasive screening method, potentially transforming heart dysfunction detection in primary care. With 6.2 million heart failure cases in the U.S. and associated costs exceeding $30 billion, the early detection capability may lead to improved patient outcomes. Semler aims to enhance healthcare effectiveness with innovative solutions.